An Open Label, Safety Study to Assess the Potential for Adrenal Suppression
| Status: | Completed |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 2 - 18 |
| Updated: | 12/8/2018 |
| Start Date: | September 2, 2016 |
| End Date: | October 16, 2017 |
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following
Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
To evaluate the potential of DSXS to suppress HPA axis function in patients with mild to
moderate plaque psoriasis.
To evaluate the efficacy parameters and adverse event (AE) profile of DSXS administered to
patients with mild to moderate plaque psoriasis.
moderate plaque psoriasis.
To evaluate the efficacy parameters and adverse event (AE) profile of DSXS administered to
patients with mild to moderate plaque psoriasis.
Inclusion Criteria:
- Male or non pregnant, non lactating females
Exclusion Criteria:
- Patients under 2 years of age
We found this trial at
1
site
Click here to add this to my saved trials
